LENZ Therapeutics 12-Month Price Target Adjusted
The average 12-month price target for LENZ Therapeutics, Inc. has been updated based on consensus estimates from seven analysts.
Stocks · News reference
HC Wainwright & Co. Maintains Buy Rating on LENZ Therapeutics, Lowers Price Target
HC Wainwright & Co. has reaffirmed its 'Buy' rating on LENZ Therapeutics while reducing its price target from $38 to $16.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Major Shareholder RA Capital Management Sells Shares of LENZ Therapeutics
RA Capital Management, L.P. disclosed the sale of over 2.7 million shares of LENZ Therapeutics common stock.
HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $16
LENZ Therapeutics Q3 2026 Earnings Call Transcript
LENZ Therapeutics (NASDAQ:LENZ) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga
LENZ Therapeutics Reports Q3 2026 Financial Results, Announces Strategic Reorganization and CEO Succession
LENZ Therapeutics reported its third-quarter 2026 financial results and announced a strategic consumer marketing-focused reorganization alongside the transition of its CEO.
8-K filing — LENZ Therapeutics, Inc. (LENZ)
Filed: 2026-10-28 AccNo: 0001815776-26-000056 Size: 304 KB Item 2.02: Results of Operations and Financial Condition Item 2.05: Cost Associated with Exit or Disposal Activities Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits